Zanubrutinib for DLBCL with specific genetic changes
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a type of lymphoma called DLBCL.
- Your tumor must have a specific genetic change (MYD88 L265P, CD79B, or NOTCH1) or be positive for CD5 (a marker on the cancer cells).
- You can have had no more than 1 cycle of R-CHOP chemotherapy before starting this trial.
- You need to have measurable disease visible on a PET/CT scan.
- Your kidneys, liver, and blood counts need to be working well enough (your doctor will check this with blood tests).
- You must not have certain serious heart conditions, active infections, or other cancers treated within the last 3 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination: zanubrutinib (a targeted pill) plus standard chemotherapy (R-CHOP) for people newly diagnosed with DLBCL whose cancer cells have high p53 protein levels. The goal is to see if adding this drug helps shrink tumors better than chemotherapy alone.
This study tests a pill called zanubrutinib as a follow-up treatment for people with DLBCL (a type of blood cancer) who are too frail or older to receive more intensive chemotherapy but whose cancer has already shrunk after initial treatment. The goal is to see if this maintenance therapy helps keep the cancer in remission and improves outcomes.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial tests a new combination of targeted therapy (pirtobrutinib) with standard chemotherapy (Pola-R-CHP) for people newly diagnosed with a type of large B-cell lymphoma that is not the germinal center B-cell subtype. The goal is to see if adding pirtobrutinib helps the treatment work better.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.